Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · IEX Real-Time Price · USD
1.440
-0.230 (-13.77%)
At close: Jul 2, 2024, 4:00 PM
1.420
-0.020 (-1.39%)
After-hours: Jul 2, 2024, 7:59 PM EDT
Carisma Therapeutics Stock Forecast
CARM's stock price has decreased by -82.86% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CARM stock have an average target of 9.00, with a low estimate of 6.00 and a high estimate of 12. The average target predicts an increase of 525.00% from the current stock price of 1.44.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CARM stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +455.56% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +455.56% | Jun 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +455.56% | May 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +455.56% | May 10, 2024 |
| BTIG | BTIG | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +316.67% | Apr 11, 2024 |
Financial Forecast
Revenue This Year
15.83M
from 14.92M
Increased by 6.13%
Revenue Next Year
9.79M
from 15.83M
Decreased by -38.16%
EPS This Year
-1.29
from -2.59
EPS Next Year
-1.27
from -1.29
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 19.3M | 16.0M | n/a | n/a | 12.8M |
| Avg | 15.8M | 9.8M | n/a | n/a | 12.4M |
| Low | 13.3M | n/a | n/a | n/a | 12.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.5% | 0.8% | - | - | - |
| Avg | 6.1% | -38.2% | - | - | - |
| Low | -10.7% | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.78 | -0.71 | -0.68 | -2.21 | -2.01 |
| Avg | -1.29 | -1.27 | -1.41 | -2.14 | -1.95 |
| Low | -1.75 | -2.03 | -2.07 | -2.06 | -1.87 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.